End User Needs and Perspectives for a Digital Opioid Safety Tool in Adolescents and Young Adults With Inflammatory Bowel Disease: A Qualitative Human-Centered Design Study.

BACKGROUND: Chronic opioid use, a key predictor of opioid overdose, is common among adolescents and young adults (AYA) with inflammatory bowel diseases (IBD), underscoring a need for tailored interventions to monitor risk for opioid-related harm. Prior research highlights the need to engage both AYA patients with IBD and IBD-focused clinicians in the development of pain management and opioid safety interventions. Human-centered design offers a promising approach to address this gap by directly engaging patients and clinicians in cocreating solutions.

OBJECTIVE: We aimed to explore and identify AYA patient and clinician perspectives to inform the design and development of a digital opioid safety tool.

METHODS: Using convenience sampling, we conducted semistructured interviews with AYA patients with IBD and IBD-focused clinicians (gastroenterologists, surgeons, and nurses) in July-August 2023 in person or by video-based conferencing. Interviews explored patient experiences with pain management, opioid use, and transitions to adult care, as well as clinician experiences in monitoring pain and prescribing opioids. A co-design workshop, following the interviews, brought patient and clinician participants together to reflect as a group on the unique challenges of managing pain in IBD care, and consider potential creative solutions to enhance pain management safety. The workshop was facilitated in person in September 2023 and included 7 patients and 8 clinicians who previously participated in individual interviews. Data were audio recorded, transcribed, and thematically analyzed using an inductive approach to identify themes.

RESULTS: Twenty participants (7 AYA patients and 13 clinicians) contributed to the study. Thematic analysis generated three domains of needs that a digital opioid safety tool should address: (1) Intersecting Needs (ie, relevant at the patient and clinician and/or health system levels), (2) Patient-Level Needs (ie, relevant at the patient level only), and (3) Clinician- and/or Health System-Level Needs (ie, relevant at the clinician and/or health system levels only). Intersecting needs included integrating opioid safety interventions into multidisciplinary chronic care, supporting AYA transitions to independence, and acknowledging individual patient differences. Patient-level needs included assessing lived experiences of pain routinely, setting clear expectations about pain management, and connecting patients with safe nonopioid alternatives. Clinician- and/or health system-level needs included accounting for pain management received outside the IBD clinic; addressing gaps in information, education, and resources regarding opioid risk or pain management; and coordinating safety efforts across clinical teams.

CONCLUSIONS: Incorporating these insights into the development of a digital opioid safety tool may enhance alignment between patient and clinician expectations on pain management and opioid use. This study underscores the value of human-centered design in developing digital opioid safety tools that are practical, patient-focused, and effectively integrated into clinical workflows. Findings may guide future intervention design, prototyping, and testing with continued engagement of AYA patients with IBD and clinicians.